

## PRESS RELEASE

### Krka Reports Q1 2026 Business Results

Novo mesto, 14 May 2026

In the first quarter of 2026, the Krka Group generated revenue of €565.8 million and operating profit of €151.6 million, confirming long-term stable sales growth and sustained operating profitability. EBITDA margin stood at 31%. The Supervisory Board of Krka discussed the Q1 2026 business report of the Krka Group and Krka at its regular meeting yesterday.

President of the Management Board and Chief Executive Officer Jože Colarič explained: 'We continued to operate successfully in the first quarter of 2026. Product and service sales increased by 8%. We recorded growth in most markets and across all product and service groups, with the exception of non-prescription products. It is important that we continue to strengthen sales and our position in our key sales regions and traditional markets. We expanded our product portfolio with three new prescription pharmaceuticals and one animal health product. For the first time, operating profit in a single quarter exceeded €150 million, up 24% year on year. Net profit for the first quarter amounted to €121 million, which was the second highest to date in Krka. Year-on-year net profit decreased by 21%, on the back of a high base effect of net financial result in the first quarter last year, while net financial result presented a slight loss this year. Compared to an average quarter of the previous year, net profit increased by 20%. We continue a range of investment projects, upgrading and expanding the capacities in Slovenia and abroad.

The Management and Supervisory Boards of Krka proposed that shareholders be paid a gross dividend of €9.10 per share for 2025, an increase of just over 10% year on year. Shareholders will vote on this proposal at the 32nd Annual General Meeting due on 9 July.'

### Krka Group financial highlights

€ thousand	Jan–Mar 2026	Jan–Mar 2025	Index
Revenue	565,774	522,114	108
– Of which revenue from sales of products and services	564,195	521,456	108
Gross profit	342,001	304,417	112
Earnings before interest, tax, depreciation and amortisation (EBITDA)	175,650	145,862	120
Operating profit (EBIT)	151,601	122,690	124
Profit before tax (EBT)	148,272	179,514	83
Net profit	120,950	152,484	79
R&D expenses	51,371	49,519	104
Investments	22,942	21,066	109

### Krka Group performance ratios


	Jan–Mar 2026	Jan–Mar 2025
Gross profit margin	60.4%	58.3%
EBITDA margin	31.0%	27.9%
EBIT margin	26.8%	23.5%
EBT margin	26.2%	34.4%
Net profit margin (ROS)	21.4%	29.2%
Return on equity (ROE)	19.9%	26.2%
Return on assets (ROA)	15.6%	20.5%
Liabilities/Equity	0.278	0.276
R&D expenses/Revenue	9.1%	9.5%

## Krka Group sales

### Product and service sales by region

€ thousand	Jan–Mar 2026	Jan–Mar 2025	Index
Region Slovenia	34,496	32,161	107
Region South-East Europe	81,988	75,019	109
Region East Europe	199,915	176,766	113
Region Central Europe	133,454	124,381	107
Region West Europe	94,969	96,074	99
Region Overseas Markets	19,373	17,055	114
<b>Total</b>	<b>564,195</b>	<b>521,456</b>	<b>108</b>

### Q1 2026 product and service sales by region



The figures in parentheses show year-on-year changes in sales by region.

Generating €199.9 million in product sales, Region East Europe was our largest region in terms of sales value. Product sales totalled €122.0 million in the Russian Federation, our largest individual market in sales value, up 28% on last year. In Ukraine, product sales reached €26.7 million, down 4% on the same period last year.

Region Central Europe, our next largest sales region, recorded product sales of €133.5 million. Product sales in Poland, our second largest individual market in sales value, reached €67.4 million, a 5% year-on-year increase. In Czechia, product sales amounted to €19.2 million (up 17%), and in Hungary to €15.8 million (up 9%). Sales also increased in all other regional markets.

Region West Europe recorded product sales of €95.0 million, ranking third in terms of sales. In Germany, the largest regional market by sales value, product sales amounted to €24.4 million, in line with the same period last year. The highest sales increases in the region were recorded in Ireland (up 16%), the United Kingdom (up 5%), and Portugal (up 4%).

Region South-East Europe generated product sales of €82.0 million. We increased sales across all regional markets except in Albania, our smallest market. In Romania, product sales totalled €20.9 million, up 2% year on year.


Product and service sales in Region Slovenia, our domestic market, totalled €34.5 million. Holding a 7.9% market share, we maintained the leading position among providers of medicines in the country.

Region Overseas Markets recorded sales growth across all markets, except in the Middle East.

## Product and service sales by group

€ thousand	Jan–Mar 2026	Jan–Mar 2025	Index
Human health products	516,145	477,202	108
– Prescription pharmaceuticals	474,091	431,584	110
– Non-prescription products	42,054	45,618	92
Animal health products	35,471	32,310	110
Health resort and tourist services	12,579	11,944	105
<b>Total</b>	<b>564,195</b>	<b>521,456</b>	<b>108</b>

## Q1 2026 product and service sales by group



The figures in parentheses show year-on-year changes in product and service sales by group.

## Research and development

In the first quarter of 2026, we expanded our product range with four new products, including three prescription pharmaceuticals and one veterinary medicine for companion animals. We market them under different brand names in individual markets.

We completed over 240 registration procedures for new and already established products in several markets.

We finalised registration procedures for three new prescription pharmaceuticals while new marketing authorisations were granted for our already established products in additional markets.

Marketing authorisations were granted to two new antidiabetic single-pill combinations formulated as film-coated tablets. Mempoglyn (empagliflozin/metformin) combines two active substances with a synergistic mode of action for a contemporary and comprehensive approach to the treatment of type 2 diabetes. Lymexo (linagliptin/metformin) is indicated for the treatment of type 2 diabetes and allows therapy to be tailored to patients' needs.

Marketing authorisation was also granted to a new formulation of Dulsevia (duloxetine) hard gastro-resistant capsules, in some markets available as Loxentia. This established medicine is used to treat central nervous system disorders like depression and anxiety, as well as pain caused by nerve damage associated with diabetes (diabetic peripheral neuropathy) in adults. At certain doses, it can also be used to treat stress urinary incontinence.

Our established products were granted new marketing authorisations in additional markets, among them Roxera Plus (rosuvastatin/ezetimibe), the single-pill combination used to treat more complicated forms of hyperlipidaemia, and an analgesic containing naproxen, both available as film-coated tablets in the European Union markets. In eastern European countries, additional approvals were granted for the single-pill combination Nalgesin Duo (naproxen/paracetamol) film-coated tablets used to relieve mild to moderate pain, the antidiabetic agent Dapafors (dapagliflozin) film-coated tablets, and the single-pill combination Valsacor INDA (valsartan/indapamide) modified-release tablets used to treat high blood

pressure. Marketing authorisations granted in markets in south-eastern Europe include single-pill combinations Mexdagry (dapagliflozin/metformin) and Dagrado (dapagliflozin/sitagliptin) film-coated tablets used to treat high blood sugar, and the single-pill combination Tolurindo (telmisartan/indapamide) modified-release tablets used to treat high blood pressure. New marketing authorisations were granted to our cardiovascular agents in overseas markets. We obtained approvals for Roswera (rosuvastatin) film-coated tablets used to treat hyperlipidaemia and Prenewel (perindopril/indapamide) tablets indicated for the treatment of hypertension.

We extended our portfolio of non-prescription products by obtaining marketing authorisations for already established brands in additional markets. Among them are Septotele Total Lemon-and-Ginger Flavoured Lozenges (benzylamine/cetylpyridinium chloride) and Septotele Total Cola-Flavoured Lozenges for relieving pain and inflammation in the oral cavity and throat, and Herbion Iceland Moss lozenges for relieving irritation of the mucosa in the throat and mouth, as well as the associated dry cough.

We expanded the range of veterinary products for companion animals with marketing authorisations for our new analgesic Robexera (robenacoxib) chewable tablets for cats, in certain markets available as Rogiola. It is used to control pain and inflammation associated with musculoskeletal diseases and relieve moderate pain and inflammation after surgery. New marketing authorisations were granted to already established animal health products in additional markets. Among them are Dehispot (praziquantel/emodepside) spot-on solution indicated for the treatment and prevention of internal parasitic infections in cats and Marinia (maropitant), also marketed as Arocenia in certain markets, used to treat and prevent nausea and vomiting in dogs and cats.

## Investments

In the first quarter of 2026, the Krka Group allocated €22.9 million to investments, of which €17.9 million to the controlling company.

The upgrades at the Notol plant in Novo mesto, Slovenia, are intended to ensure reliable operations over the next 20 years, alongside an extension designed to increase production capacity. The installation of additional equipment at Notol 2, another production plant in Novo mesto, Slovenia, will further boost production capacities.

We completed the investment in additional capacities for tableting mixture preparation, granulation, and logistics at the Solid Dosage Products plant in Novo mesto, Slovenia.

We installed a new suspension inspection line at the Sterile Products Department in Novo mesto, Slovenia, and finished construction of an extension for a new sterile solutions production line in order to significantly enhance the capacity.

Construction of a multi-purpose building at our central site in Ločna, Novo mesto, Slovenia, is nearing completion. At the Laguna site in Novo mesto, Slovenia, activities for the construction of another multi-purpose building continue.

We started the construction of a facility at the Bršljin Department in Novo mesto, Slovenia, to increase production and packaging capacity for animal health products. We also expect to boost the capacity for packaging tablets for use in veterinary medicine and spot-on solutions in the existing facility.

We finished the capacity expansion at the Ljutomer plant in Slovenia. Construction of an automated high-bay warehouse and an expansion of the plant are underway.

We completed construction of the technically and technologically advanced waste water treatment plant in Krško, Slovenia. Pre-treatment technology has been in operation since September 2025, and the remaining biological treatment stages will be brought into operation gradually.

We are currently increasing production capacity at the production and distribution centre in Jastrebarsko, Croatia.

An extensive refurbishment of the Hotel Vital in Dolenjske Toplice, Slovenia, is in progress to improve patient accommodation. In Strunjan, also in Slovenia, the planned reconstruction of Villa Rožmarin continues the development of tourism infrastructure.

We set up product manufacturing in China to support animal health products programme. We installed and qualified a filling-and-packaging line.

Construction of research and production facilities for oncology products and solid dosage forms is underway at Krka Pharma Private Limited, a joint venture in Hyderabad, India.

## Employees

At the end of March 2026, the Krka Group had 13,204 employees on its payroll, with 5,519 or 42% working outside Slovenia. The Krka Group employed 13,261 persons, including agency workers. Overall, 47% of employees held at least a university degree, of whom 206 held doctoral degrees.

## Investor and share information

The Krka share price on the Ljubljana Stock Exchange rose by 14.8% over the first three months of 2026, standing at €233.00 on 31 March 2026. The ownership structure remained stable, as there were no significant changes during this period. At the end of March 2026, Krka had 48,201 shareholders. The market capitalisation of Krka on the Ljubljana Stock Exchange, including treasury shares, totalled €7.6 billion as at 31 March 2026. The average daily trading volume of Krka shares during this period amounted to €1.1 million.

In the first quarter of 2026, Krka acquired 59,459 treasury shares and held 2,494,286 treasury shares as at 31 March 2026, representing 7.606% of its share capital.

## Sustainable operations

Sustainable operations and governance have long been a cornerstone of the Krka Group's stable development and are fully integrated in our business processes. Our strategic sustainability areas are interlinked with the three strategic pillars of the *2026–2030 Krka Group Development Strategy*. The annual report published on 9 April 2026 includes our second sustainability statement, prepared in accordance with the *European Sustainability Reporting Standards (ESRS)*. Compliance with the standards was also confirmed by an external auditor. The statement presents key information on sustainability impacts, risks and opportunities, as well as how they are managed. The ESG rating of 55/100 awarded by S&P Global confirms the established direction of the Krka Group in sustainable operations and governance.

## 2026 Krka Group plans

The Krka Group plans revenue of €2.144 billion and net profit of €405 million for 2026. We intend to allocate over €140 million to investments, primarily for expanding and modernising production facilities and infrastructure. We earmarked €20 million for our joint venture, Krka Pharma Private Limited, in India.

The semi-annual 2026 performance estimate will be released at the 32nd regular Annual General Meeting on 9 July 2026, followed by the publication of the 2026 semi-annual report on 23 July 2026.